Furthermore, political aspects of culture-in-relationto-psychiatry are of particular importance at the present time. It appears that there must be an anthropology of psychiatry as well as a sociology of it, and a sociology of anthropology. In addition, it appears important to give medical students a cultural perspective on disease and healing, for people's beliefs about their diseases and their outcomes contribute to these outcomes and require anthropological insights for their understanding. For instance, rituals are important for people everywhere in relation to birth, death, and the transitions which occur as a person passes from one to the other, and doctors need to understand this, with the necessary anthropological concepts. Certainly to equate anthropology with 'ethnic minorities and how to cope with them' is a serious mistake. Anthropology is a serious discipline, studies of groups of different racial origin in relation to each other being only one of its fields.
Psychology is now vast in scope and pre-eminent among the behavioural and social sciences in its relevance for psychiatry. Perhaps 'potential relevance' would be nearer the mark, for it seems that few psychiatrists at present seriously attempt to apply the findings of the various branches of psychology to psychiatric subject matter. For instance, occupational, cognitive, developmental, physiological, and social psychology are all largely ignored in current Britishpsychiatric texts and in the regulations for Membership of the Royal College of Psychiatrists. Explorations yet to be made could illumine much current psychiatric practice.
In social psychology, for instance, emotion has received renewed attention in recent years. Vocal aspects of emotion can now be reliably measured and shown to indicate different emotional states, shedding modern light on the classic James-Lange theory of emotion and also clarifying Schacter's 1960s' idea that it was the cognitive 'addition' to physiological arousal which gave one emotion rather than another. Nonverbal aspects of emotional behaviour are also now susceptible to measurement; these include facial expression, gesture, and aspects of interaction. The increased sophistication, availability, and ease of use of video and computer technologies have facilitated these advances. Improved methods of studying interaction, giving moment-by-moment data about communication and information-sharing processes, for example, are particularly promising for psychiatry, where interpersonal relationships (not the same as interaction but obviously related to it) are vitally important throughout the field and hitherto have often been assessed without direct observation of interaction between the people concerned.
Many other examples could be given of ways in which modern psychology could usefully be applied to psychiatry. An important reason for the relative lack of contact between these subjects in Britain concerns their usually being administered in different parts of universities. Easier intercollegiate arrangements would greatly ease this problem. Another difficulty is of course the relatively 'Cinderella' status of both psychology within science and psychiatry within medicine. The levels of resource available for these subjects from public funds in Britain are now so low that it is a tribute to the workers concerned that any research is done at all. Without sustained additional support, the advances waiting to be made will be made other than in the United Kingdom. 
J P Watson

Medicines from new biotechnologies
Progress in the biomedical sciences and the exploitation of advanced biotechnologies are presently leading to the development of new biological medicinal products at an unprecedented rate. Developments in molecular genetics and nucleic acid chemistry now enable genes coding for natural biologically active proteins to be identified, analysed in fine detail and transferred from one organism to another so as to obtain highly efficient synthesis of their products. This is the basis of recombinant DNA (rONA) technology, often called genetic engineering. Genes coding for modified products, possessing enhanced biological activities and/or diminished undesirable characteristics, as well as for entirely novel substances, can also be constructed.
Much genetic engineering has been carried out in bacteria, but other systems involving yeasts or continuously growing (transformed) cell lines of mammalian origin have been developed recently and some are already in use for production. The use of animal cells as hosts is considered by some to offer distinct advantages over bacterial systems. They can, for example, effect many of the modifications which normally take place on the backbone of mammalian proteins, such as the addition of carbohydrate groups and mammalian cells are thought more likely than bacteria to produce correctly folded and processed 'human' proteins. Transformed mammalian cell lines are also being considered as substrates for the manufacture of conventional products such as viral vaccines. In addition, the fusion of Bslymphocytes from immunized animals with myeloma cells,resulting in the formation of hybrid cells known as hybridomas, can lead after cloning to the production of antibodies of highly defined specificity known as monoclonal antibodies.
Together, these technologies allow the production of large quantities of useful medicinal products which are difficult to prepare from natural sources using conventional approaches or were previously unavailable. These products include, for example, hepatitis B vaccine, interferons, tumour necrosis factor, insulin, growth hormone, erythropoietin, and tissue plasminogen activator, as well as monoclonal antibodies for imaging and therapy. They have extensive implications in the prevention, diagnosis or treatment of such diverse conditions as hepatitis, cancer, diabetes and myocardial infarction.
However, there are potential safety concerns arising from the novel processes used in the manufacture of these biologicals and from the complex structural and biological characteristics of the products themselves. For example, products from naturally occurring genes made in foreign hosts may deviate structurally, biologically or immunologically from their natural counterparts. Other products may be entirely novel in structure, produced by manipulation of naturally occurring genes or by the chemical synthesis of new ones. Such products may be designed to have enhanced biological features and/or diminished undesirable effects compared with their natural counterparts. However, they may also have unexpected and undesirable biological properties in man. Furthermore, recombinant DNA (rDNA) derived products may contain potentially hazardous contaminants not normally present in their equivalents prepared by conventional methods and which the purification processes must be shown to be capable of removing. Examples ofthese are endotoxins in products expressed in bacterial cells, and contaminating cellular DNA and viruses in products derived from transformed mammalian cells.
The production of substances by these new technologies for both human and veterinary application, thus raises important issues concerning their regulation and quality control. All are considered to be 'new drugs', even though they may have conventionally produced equivalents. Adequate control measures are essential, both to safeguard patients against adverse effects and to ensure that they are given the full benefits of scientific innovation. Quite clearly, recent developments both in the nature and production of these biologicals are highly sophisticated and they require similar sophisticated laboratory techniques to ensure their proper standardization and control. Although comprehensive characterization of the final product will be expected, considerable emphasis must also be given to 'in-process' control, a concept which has been highly effective in the quality control of biological products made by conventional means. In this context, the term 'biological product' is used for those substances, generally proteins or glycoproteins, whose purity, potency or identity cannot be completely characterized by chemical and physical means alone. For these types of substances, tests on the starting materials as well as evaluation of the manufacturing process are considered to provide important information. Thus, data on the quality and purity of seed cultures and cell substrates and on the effectiveness of purification and test methods will be required. Independent testing of samples taken from any point in the production process may also be necessary and evidence will be required of the consistency of the production process and of the quality of the final product during full-scale manufacture.
Given the need to ensure the safety, efficacy and consistency of medicines produced by the new technologies, guidelines for the control and standardization of these substances destined for use in man have been developed by several organizations. For example, the National Institute for Biological Standards and Control (NIBSC) in the UK! and the Food and Drug Administration (FDA) in the USA2,3, the WH04,5 and more recently the EEC6,7, have all drafted guidelines designed to help manufacturers assemble the information needed to support applications for clinical trial certificates and product licences for monoclonal antibodies and rDNA derived products.
The intention of such guidelines is to provide a sound, scientifically justified basis for the development of medicinal products by new biotechnologies, whilst at the same time ensuring adequate protection for patients. Therefore, all adopt a flexible approach to control so that requirements can be updated in the light of experience of production and use, and with further development of new technologies. It is also appreciated that whilst such guidelines can be considered to be generally applicable, individual products will, nevertheless, exhibit their own peculiarities so that the production and quality control of each product must be considered on an individual basis. Furthermore, the implementation of requirements for a product must reflect its intended clinical use. Thus, a substance which is to be administered repeatedly or in large doses is likely to need rigorous examination for traces of antigenic contaminants. A product intended for use in a life-threatening disease, however, might justifiably require different criteria.
In all cases the guidelines have been formulated bearing in mind the conditions required for commercial production. Extensive 'scale-up' is usually required as laboratory developments progress to fullscale production, and this may have considerable consequences for the quality of the product and thus implications for control testing. Unintended variability in the culture during production may, for example, lead to changes which favour the production of proteins encoded by other genes in the hostvector system or which cause alterations in the polypeptide product. Such variations might result in decreased yield and/or quantitative and qualitative differences in the impurities present in the product. All guidelines therefore emphasize the need to ensure the consistency of production conditions as well as the final product.
For convenience, evaluation procedures are usually placed under three broad headings: (1) control of starting materials, which includes baseline data on the host cell and on the source, nature, and sequence of the gene used in production; (2) control of manufacturing process; (3) control of final product. Not all tests need necessarily be carried out on each batch of product. Some tests will be required only to establish the validity or acceptability of a process, whilst others may be performed on a limited series of batches in order to provide data on the consistency of the product and its production. In view of the special problems related to rDNA-derived products already discussed, rigorous characterization of the. substance is also required. It will be expected that the way in which a product differs from any naturally occurring equivalent will be fully documented, as will its purity with respect to host-cell derived proteins, nucleic acids, viruses and other unwanted impurities. Purification procedures which make use of affinity chromatography using biological substances such as monoclonal antibodies should include measures to ensure that these substances, or any additional potential contaminants arising from their use, such as extraneous viruses, do not compromise the safety of the final product.
In addition to developing guidelines for the quality control of the substances themselves, the EEC is presently considering the pre-clinical safety testing of new products derived by modern biotechnology. These products pose special problems since, in general, classical toxicological studies in animals as applied to chemical drugs may be of only limited relevance. For example, certain proteins, such as human interferons, are highly species-specific and are thus much more pharmacologically active in man than in any other animal species. In addition, the amino acid sequences of human proteins will often be significantly different from their natural counterparts in other animals. These proteins therefore frequently produce immunological responses in foreign hosts which may ultimately modify their biological effects and which may result in toxicity due to immune complex formation. Such toxicity would, of course, have little bearing on the safety of the product in man, the intended recipient. Nevertheless, preclinical safety testing is important, especially where repeated, large or non-physiological doses of a particular product may be required for a given therapeutic effect, and knowledge of its biological effects in man remains incomplete.
Since 1 July 1987 there has been a requirement that all product licence applications for biotechnologyderived biologicals within the EEC be referred to the Committee for Proprietary Medicinal Products or the Committee for Veterinary Medicinal Products, as the case may be, in Brussels, for an opinion's". Member States are required to take this opinion into consideration when considering the licensing of the product in question. It is hoped that the experience gained from this newly established system will help decide the most appropriate European regulatory procedures for the next decade. This development forms part of the EEC's increasing activity in developing a Communitywide framework for regulating biotechnology. It includes not only the elaboration of procedures to harmonize the regulatory approaches of Member States with regard to the licensing of biological medicines, but also procedures for regulating the levels of containment for genetically engineered organisms in enclosed manufacturing systems, as well as the control of planned release of genetically engineered organisms into the environment. In recent years a number of numerically based methods, including decision-support systems, diagnostic systems, expert systems and decision analysis, have been applied to medical practice. Whilst succeeding in pilot sites, they have failed to become part of routine medicine. Two recent reviews summarize the current position regarding decision analysis'r'. This technique was developed in the 1940s by Abraham Wald", It gives a complete and coherent description, in numerical terms, ofdecision-making under uncertainty. The advantages ofdecision analysis include guidance on which decision to take, and comparison of the effects of different decisions taken under similar circumstances. 'What if . . .1' questions can be asked to note the effects of changing the initial conditions. This tests the stability of a decision and determines the circumstances required for the decision to change. Finally, the method is objective and hence reproducible.
M F Cuthbert
Critics have pointed out some difficulties with the technique. It is said to be a complex topic, little understood by the majority, with only a few individuals able to teach it and develop it further. Using decision analysis can be time-consuming and the results are inevitably an approximation, not fully reflecting the real situation. Doctors wishing to use the method have to work in the unfamiliar environment ofmathematics and computers.
Protagonists'' argue that the method makes the decision process explicit, giving the opportunity for the elements of a decision to be isolated and examined. This provides a framework to determine reasons why different decisions occur in similar situations. Patient interests are accounted for, as their preferences can be specifically included in the method.
